King Pharmaceuticals((R)), Inc. (NYSE KG) announced that the U.S. Food and Drug Administration (FDA) has approved EMBEDA(TM) (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules for oral use, a longacting Schedule II opioid analgesic for the management of moderate to severe pain when a continuous, aroundtheclock opioid analgesic is needed for an extended period [...]